Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Vertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.

Follow Add to Watchlist Ask Question

NASDAQ VRTX Coverage Bootstrap Vertex Pharmaceuticals Incorporated

Latest ReportMay 19, 2026Vertex: the CF cash engine still has to prove the next pipeline legView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.